



Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at the 5th International Conference on Tumor Microenvironment and Cellular Stress

FREMONT, Calif., June 5, 2018 -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data by its collaborator, the University of Auckland, from ongoing studies of Rain's lead candidate, Tarloxotinib, at the 5th International Conference on Tumor Microenvironment and Cellular Stress: Signalling Metabolism, Imaging and Therapeutic Targets being held June 8-13, 2018 in Chania, Crete, Greece. An oral presentation will detail the discovery of the plasma membrane reductase responsible for activating Tarloxotinib at the site of the tumor, and a poster presentation will discuss data collected in studies of Tarloxotinib that reveal favorable *in vivo* properties to be a treatment strategy for patients with EGFR / HER Exon 20 insertion mutations in non-small cell lung cancer (NSCLC).

Details on the presentations by the University of Auckland's Translational Therapeutics team are as follows:

Poster Presentation Title: Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies

Presenter: Victoria Jackson-Patel

Date/Time: June 9, 2018 at 10:30 am EEST

Oral Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib

Session: Session XI: Clinical-Therapeutic implications

Presenter: Adam V Patterson, Ph.D.

Date/Time: June 12, 2018 at 1:30 pm EEST

Additional details can be found on the [conference website](#). A copy of presentation materials can be accessed by visiting the [Science and Publications](#) section of the Rain website after the presentations conclude.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain's lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.

The Translational Therapeutics Team is an oncology research group led by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia-activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945

cait@lifescipublicrelations.com